The National Medical Products Administration (NMPA) has updated its drug approval and certificate access process, improving transparency and digital accessibility for pharmaceutical stakeholders. The latest approved drug list (effective 03-Dec-2025) includes a wide range of traditional Chinese medicines and modern formulations from major domestic manufacturers.

Key Highlights:

  • Digital Certificate Access Enhanced:
    • Since 01-Nov-2022, individuals facing administrative penalties can still access electronic drug approval documents via the NMPA Government Service Portal.
  • Newly Approved Drug List Published:
    • Includes traditional Chinese medicines, chemical formulations, and modern pharmaceutical products.
    • Features products from multiple companies including Shanghai Shangyao Xinyi, Beijing Taide Pharmaceutical, and others.
  • Improved Tracking & Transparency:
    • Each product is assigned a unique registration number and approval validity period, strengthening regulatory traceability.
  • Industry Impact:
    • Reflects growing participation of local and international companies in China’s pharmaceutical market.
    • Supports wider availability of treatment options across therapeutic areas.

Consult Now

Source
https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20251209164150194.html
Select Mandate HA
NMPA
Select Mandate Function
Regulatory Affairs